Published in Br J Pharmacol on April 01, 2000
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Control of sleep and wakefulness. Physiol Rev (2012) 3.06
Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci U S A (2003) 1.48
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.37
Do initial responses to drugs predict future use or abuse? Neurosci Biobehav Rev (2012) 1.26
The effects of caffeine on sleep in Drosophila require PKA activity, but not the adenosine receptor. J Neurosci (2009) 1.21
Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. Life Sci (2009) 1.13
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation. Br J Pharmacol (2012) 1.02
Caffeine accelerates recovery from general anesthesia. J Neurophysiol (2013) 0.99
Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice. Proc Natl Acad Sci U S A (2003) 0.94
Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci (2014) 0.93
A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology (Berl) (2005) 0.93
Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine. J Appl Physiol (1985) (2008) 0.92
Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol (2001) 0.89
A role for dopamine-mediated learning in the pathophysiology and treatment of Parkinson's disease. Cell Rep (2012) 0.88
Uncovering multiple molecular targets for caffeine using a drug target validation strategy combining A 2A receptor knockout mice with microarray profiling. Physiol Genomics (2009) 0.88
Caffeine and a selective adenosine A2A receptor antagonist induce reward and sensitization behavior associated with increased phospho-Thr75-DARPP-32 in mice. Psychopharmacology (Berl) (2009) 0.88
"Wired," yet intoxicated: modeling binge caffeine and alcohol co-consumption in the mouse. Alcohol Clin Exp Res (2014) 0.85
Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. Neuropharmacology (2012) 0.84
Adenosine signaling in striatal circuits and alcohol use disorders. Mol Cells (2013) 0.83
Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists. Psychopharmacology (Berl) (2011) 0.83
The Impact of Caffeine on the Behavioral Effects of Ethanol Related to Abuse and Addiction: A Review of Animal Studies. J Caffeine Res (2013) 0.82
Binding of adenosine receptor ligands to brain of adenosine receptor knock-out mice: evidence that CGS 21680 binds to A1 receptors in hippocampus. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.82
Perinatal caffeine, acting on maternal adenosine A(1) receptors, causes long-lasting behavioral changes in mouse offspring. PLoS One (2008) 0.82
Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism. ACS Chem Biol (2014) 0.80
Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Transl Psychiatry (2015) 0.80
Sex differences in caffeine neurotoxicity following chronic ethanol exposure and withdrawal. Alcohol Alcohol (2009) 0.80
Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling. Brain Res (2006) 0.77
Injection of Cocaine-Amphetamine Regulated Transcript (CART) peptide into the nucleus accumbens does not inhibit caffeine-induced locomotor activity: Implications for CART peptide mechanism. Pharmacol Biochem Behav (2016) 0.77
Adenosine A(2A) receptors are necessary and sufficient to trigger memory impairment in adult mice. Br J Pharmacol (2015) 0.77
Caffeinated Alcoholic Beverages - An Emerging Trend in Alcohol Abuse. J Addict Res Ther (2013) 0.77
Evidence for the role of nitric oxide in caffeine-induced locomotor activity in mice. Psychopharmacology (Berl) (2003) 0.77
Effect of Various Antiepileptic Drugs in Zebrafish PTZ-Seizure Model. Indian J Pharm Sci (2014) 0.77
Adenosine receptor antagonists and behavioral activation in NF-kappaB p50 subunit knockout mice. Life Sci (2009) 0.76
Adenosinergic regulation of striatal clock gene expression and ethanol intake during constant light. Neuropsychopharmacology (2014) 0.76
Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms. Neuropharmacology (2016) 0.75
Effects of caffeine on locomotor activity in streptozotocin-induced diabetic rats. J Med Life (2016) 0.75
Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia. Br J Pharmacol (2001) 0.75
Caffeine impairs the acquisition and retention, but not the consolidation of Pavlovian conditioned freezing in mice. Psychopharmacology (Berl) (2014) 0.75
Caffeine and sleep-deprivation mediated changes in open-field behaviours, stress response and antioxidant status in mice. Sleep Sci (2016) 0.75
Caffeine stimulates locomotor activity in the mammalian spinal cord via adenosine A1 receptor-dopamine D1 receptor interaction and PKA-dependent mechanisms. Neuropharmacology (2015) 0.75
An undergraduate laboratory exercise examining the psychomotor stimulant effects of caffeine in laboratory rats. J Undergrad Neurosci Educ (2012) 0.75
Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.75
Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science (1989) 6.67
Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev (1999) 6.26
Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem (1979) 5.92
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature (1997) 3.75
Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem (1989) 2.75
Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci U S A (1981) 2.66
Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci (1997) 2.23
RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem Biophys Res Commun (1990) 1.94
The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. EMBO J (1991) 1.57
Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol (1995) 1.52
8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett (1993) 1.47
Interchangeability of stress and amphetamine in sensitization. Science (1980) 1.43
Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J Pharmacol Exp Ther (1982) 1.33
Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J Pharmacol Exp Ther (1991) 1.31
3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs. Life Sci (1988) 1.26
Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci (1996) 1.23
Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) (1997) 1.19
Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology (Berl) (1989) 1.17
Effects of N6-cyclopentyladenosine and caffeine on sleep regulation in the rat. Eur J Pharmacol (1996) 1.13
Caffeine intake, tolerance, and withdrawal in women: a population-based twin study. Am J Psychiatry (1999) 1.08
Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry (1985) 1.07
[Action of caffeine on the spontaneous motility of the mouse]. Arch Int Pharmacodyn Ther (1965) 1.06
Hypothalamic-pituitary-adrenocortical responses to psychological stress and caffeine in men at high and low risk for hypertension. Psychosom Med (1998) 1.03
Effects of isolation, handling and novelty on the pituitary--adrenal response in the mouse. Psychoneuroendocrinology (1982) 1.02
Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J Pharmacol Exp Ther (1989) 1.02
Involvement of adenosine A2A receptor in sleep promotion. Eur J Pharmacol (1998) 1.00
A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res (1997) 1.00
Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J Neurosci (1995) 0.99
Reinforcing effects of caffeine in humans. J Pharmacol Exp Ther (1988) 0.99
Effects of caffeine and theophylline on activity of rats in relation to brain xanthine concentrations. Proc Soc Exp Biol Med (1972) 0.96
Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience (1997) 0.96
Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques. J Pharmacol Exp Ther (1998) 0.95
Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol Biochem Behav (1993) 0.93
Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Arch Gen Psychiatry (1984) 0.92
Interactions in the behavioral effects of methylxanthines and adenosine derivatives. J Pharmacol Exp Ther (1983) 0.91
Potential use of DPCPX as probe for in vivo localization of brain A1 adenosine receptors. Brain Res (1992) 0.91
Anxiolytic activity of adenosine receptor activation in mice. Br J Pharmacol (1995) 0.90
Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline- and pentylenetetrazol-induced seizures in mice. Relationship to c-fos expression and receptor binding. Eur J Neurosci (1996) 0.89
NECA-induced hypomotility in mice: evidence for a predominantly central site of action. Pharmacol Biochem Behav (1989) 0.88
The dose-response effects of caffeine on sleep in rats. Brain Res (1987) 0.87
Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX. Psychopharmacology (Berl) (1991) 0.87
Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology (1992) 0.86
Inhibition of nigrostriatal release of dopamine in the rat by adenosine receptor agonists: A1 receptor mediation. Neuropharmacology (1989) 0.82
Inherent differences in sensitivity to methylxanthines among inbred mice. Pharmacol Biochem Behav (1986) 0.82
The differential role of A1 and A2 adenosine receptor subtypes in locomotor activity and place conditioning in rats. Behav Pharmacol (1996) 0.81
Central effects of corticotropin releasing factor (CRF): evidence for similar interactions with environmental novelty and with caffeine. Psychopharmacology (Berl) (1990) 0.81
Caffeine: relationship to human anxiety, plasma MHPG and cortisol. Psychopharmacol Bull (1984) 0.81
Differential role of nucleus accumbens and caudate-putamen in mediating the effect of nomifensine and methamphetamine on ambulation and rearing of rats in the open-field test. Jpn J Pharmacol (1995) 0.80
Inhibitory and excitatory effects of adenosine antagonists on spontaneous locomotor activity in mice. Life Sci (1997) 0.79
Neuroendocrine effects of caffeine. II. Effects on thyrotropin and corticosterone secretion. J Pharmacol Exp Ther (1983) 0.79
Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, D-amphetamine, and methylphenidate. Neuropharmacology (1990) 0.79
CGS 15943, a nonxanthine adenosine receptor antagonist: effects on locomotor activity of nontolerant and caffeine-tolerant rats. Life Sci (1991) 0.78
Effect of caffeine on locomotor activity and central catecholamine mechanisms: a study with special reference to drug interaction. Acta Pharmacol Toxicol (Copenh) (1975) 0.77
Adenosine receptors. Knockouts anxious for new therapy. Nature (1997) 0.77
Caffeine as an intensifier of stress-induced hormonal and pathophysiologic changes in mice. Pharmacol Biochem Behav (1980) 0.77
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science (1989) 6.67
Cloning of genomic DNA for human atrial natriuretic factor. Biochem Biophys Res Commun (1984) 6.53
The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem (2001) 4.77
Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry (1996) 4.35
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 4.31
ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett (1994) 3.78
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature (1997) 3.75
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med (1997) 3.48
Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell (1996) 3.44
Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem (1999) 3.35
Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci (2000) 2.69
Unplanned extubation: risk factors of development and predictive criteria for reintubation. Crit Care Med (1998) 2.68
Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol (1997) 2.51
Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci (2001) 2.48
Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci U S A (1997) 2.34
Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J (1991) 2.23
Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res (1994) 2.20
Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci (2001) 2.15
Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem (1997) 2.12
Identification of a novel human ADP receptor coupled to G(i). J Biol Chem (2001) 2.05
Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience (2001) 2.05
RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem Biophys Res Commun (1990) 1.94
Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol (2001) 1.94
ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J Immunol (1998) 1.88
Expression of members of the putative olfactory receptor gene family in mammalian germ cells. Nature (1992) 1.79
CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood (1999) 1.75
Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. J Virol (1999) 1.72
Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun (1996) 1.71
Cloning and functional expression of a human uridine nucleotide receptor. J Biol Chem (1995) 1.68
The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet (1998) 1.67
The second extracellular loop of CCR5 is the major determinant of ligand specificity. J Biol Chem (1997) 1.62
The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. EMBO J (1991) 1.57
Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Commun (1989) 1.57
Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology (Berl) (1976) 1.57
Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci (2004) 1.55
Rapid and dissociated changes in sensitivities of different dopamine receptors in mouse brain. Nature (1975) 1.54
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci (2002) 1.52
Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. J Leukoc Biol (1999) 1.50
Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res (2001) 1.46
Evidence of a cohort effect for age at onset of schizophrenia. Am J Psychiatry (2001) 1.44
Effects of pressure ramp slope values on the work of breathing during pressure support ventilation in restrictive patients. Crit Care Med (1999) 1.42
Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology (1996) 1.42
The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem (1998) 1.42
Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood (2001) 1.39
[Smoking and pregnancy: survey among women enrolled in an independent worker insurance program]. J Gynecol Obstet Biol Reprod (Paris) (2004) 1.39
The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J Biol Chem (2001) 1.37
Impaired motor coordination and Purkinje cell excitability in mice lacking calretinin. Proc Natl Acad Sci U S A (1999) 1.37
Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J Biol Chem (1999) 1.36
Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem (1999) 1.34
CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol (2004) 1.34
CC chemokine MIP-1 beta can function as a monomer and depends on Phe13 for receptor binding. Biochemistry (2000) 1.33
Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett (1998) 1.33
Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci U S A (2000) 1.30
Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology (2002) 1.29
Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry (2001) 1.28
Specific repertoire of olfactory receptor genes in the male germ cells of several mammalian species. Genomics (1997) 1.27
Stable expression of the human TSH receptor in CHO cells and characterization of differentially expressing clones. Biochem Biophys Res Commun (1990) 1.27
Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci (2000) 1.25
Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways. J Biol Chem (2001) 1.24
Importance of basic residues and quaternary structure in the function of MIP-1 beta: CCR5 binding and cell surface sugar interactions. Biochemistry (2001) 1.21
Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci (2001) 1.20
Is presentation of bacteremia in the elderly the same as in younger patients? Am J Med (1996) 1.19
Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol (1999) 1.19
Molecular cloning, functional expression and pharmacological characterization of a human bradykinin B2 receptor gene. Biochem Biophys Res Commun (1992) 1.17
Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood (2000) 1.16
Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase. Biochem J (1995) 1.14
Cloning and tissue distribution of the human P2Y1 receptor. Biochem Biophys Res Commun (1996) 1.14
Complete nucleotide sequence of a putative G protein coupled receptor: RDC1. Nucleic Acids Res (1990) 1.14
The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists. Psychopharmacology (Berl) (2000) 1.13
Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur J Pharmacol (1996) 1.11
The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3. Genomics (1996) 1.11
Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc (1996) 1.11
Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J Neurochem (2001) 1.11
The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci (2004) 1.11
The orexin OX1 receptor activates a novel Ca2+ influx pathway necessary for coupling to phospholipase C. J Biol Chem (2000) 1.09
Chromosomal mapping of A1 and A2 adenosine receptors, VIP receptor, and a new subtype of serotonin receptor. Genomics (1991) 1.09
Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med (2000) 1.08
Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol (2004) 1.05
Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. Biochemistry (1994) 1.05
The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. Biochem Biophys Res Commun (2001) 1.04
Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci U S A (1996) 1.03
Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry (2005) 1.02
A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission. Neurology (2003) 1.02
Thyroid adenocarcinomas secondary to tissue-specific expression of simian virus-40 large T-antigen in transgenic mice. Endocrinology (1991) 1.02
Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan. Proc Natl Acad Sci U S A (1983) 1.01
Functional characterization of a human receptor for neuropeptide FF and related peptides. Br J Pharmacol (2001) 1.01